Readnour Robin Shane
Insider CIK 1914883 · ANTX Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-09 | 2026-09-11 | 523 | $6.02 | $3.1K | 557,467 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-09 | 2026-09-11 | 585 | $6.02 | $3.5K | 624,765 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-09 | 2026-09-11 | 585 | $6.02 | $3.5K | 624,765 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-09 | 2026-09-11 | 523 | $6.02 | $3.2K | 557,467 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-08 | 2026-09-08 | 5,294 | $6.02 | $31.9K | 625,350 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-08 | 2026-09-08 | 4,725 | $6.02 | $28.4K | 557,990 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-08 | 2026-09-08 | 5,294 | $6.02 | $31.9K | 625,350 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-08 | 2026-09-08 | 4,725 | $6.02 | $28.4K | 557,990 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-03 | 2026-09-08 | 3,223 | $6.07 | $19.6K | 630,644 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-03 | 2026-09-08 | 2,877 | $6.07 | $17.5K | 562,715 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-03 | 2026-09-08 | 3,223 | $6.07 | $19.6K | 630,644 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-09-03 | 2026-09-08 | 2,877 | $6.07 | $17.5K | 562,715 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 18,706 | $6.01 | $112.4K | 633,867 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 16,696 | $6.01 | $100.3K | 565,592 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 18,706 | $6.01 | $112.4K | 633,867 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2026-08-17 | 2026-08-19 | 16,696 | $6.01 | $100.3K | 565,592 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2026-03-19 | 2026-03-23 | 23,742 | — | $0 | 23,742 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | D To issuer deriv | 2026-03-19 | 2026-03-23 | 20,724 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2026-03-19 | 2026-03-23 | 20,724 | — | $0 | 20,724 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | D To issuer deriv | 2026-03-19 | 2026-03-23 | 23,742 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2026-02-20 | 2026-02-23 | 20,400 | — | $0 | 20,400 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2025-05-22 | 2025-05-23 | 19,111 | — | $0 | 19,111 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award | 2024-12-19 | 2024-12-23 | 9,077 | — | $0 | 9,077 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-10 | 2024-12-10 | 5,000 | $1.49 | $7.5K | 582,288 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-10 | 2024-12-10 | 5,000 | $1.49 | $7.5K | 652,573 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-09 | 2024-12-10 | 12,289 | $1.43 | $17.6K | 577,288 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-09 | 2024-12-10 | 18,483 | $1.43 | $26.4K | 647,573 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-06 | 2024-12-10 | 12,711 | $1.45 | $18.4K | 564,999 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-12-06 | 2024-12-10 | 6,517 | $1.45 | $9.4K | 629,090 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-27 | 2024-11-27 | 25,000 | $1.42 | $35.5K | 552,288 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-27 | 2024-11-27 | 25,000 | $1.42 | $35.5K | 622,573 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-26 | 2024-11-27 | 12,500 | $1.39 | $17.4K | 527,288 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-26 | 2024-11-27 | 12,500 | $1.39 | $17.4K | 597,573 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-20 | 2024-11-21 | 25,000 | $1.16 | $29.0K | 585,073 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-20 | 2024-11-21 | 25,000 | $1.15 | $28.7K | 514,788 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-19 | 2024-11-21 | 75,000 | $1.03 | $77.3K | 560,073 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2024-11-19 | 2024-11-21 | 75,000 | $1.04 | $78.0K | 489,788 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2024-06-19 | 2024-06-21 | 64,503 | — | $0 | 64,503 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-12 | 2024-01-17 | 719 | $21.91 | $15.8K | 485,073 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-12 | 2024-01-17 | 706 | $21.92 | $15.5K | 414,788 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-10 | 2024-01-12 | 1,800 | $21.92 | $39.5K | 485,792 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | S Sale | 2024-01-10 | 2024-01-12 | 1,869 | $21.93 | $41.0K | 415,494 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2023-06-07 | 2023-06-09 | 23,742 | — | $0 | 23,742 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | A Award deriv | 2022-05-12 | 2022-05-16 | 20,724 | — | $0 | 20,724 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 333,135 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 61,491 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 285,156 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion deriv | 2022-03-29 | 2022-03-31 | 71,839 | — | $0 | 0 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-03-29 | 2022-03-31 | 82,618 | $15.00 | $1.24M | 487,592 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | P Buy | 2022-03-29 | 2022-03-31 | 70,716 | $15.00 | $1.06M | 417,363 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 71,839 | — | $0 | 404,974 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 61,491 | — | $0 | 346,647 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 333,135 | — | $0 | 333,135 | SEC↗ |
| ANTX AN2 Therapeutics, Inc. | C Conversion | 2022-03-29 | 2022-03-31 | 285,156 | — | $0 | 285,156 | SEC↗ |